Home › Research › Treatments
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial
Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM et al.. JAMA neurology, 2021-11-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results Of 54 adults assessed for eligibility, 11 did not meet study criteria, and 9 declined to participate. Overall, treatment with levetiracetam did not change NIH-EXAMINER composite scores (mean difference vs placebo, 0.07 points; 95% CI, -0.18 to 0.32 points; P = .55) or secondary measures.
What this study adds
Evidence grade: High
This is a trial of 34 participants. In this randomized clinical trial, treatment with levetiracetam did not change NIH-EXAMINER composite scores or secondary measures compared with placebo. Reported effect size: 61.8%; 38.2%; 82.4%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vossel, K., Ranasinghe, K. G., Beagle, A. J., La, A., Ah Pook, K., Castro, M., et al. (2021). Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial. JAMA neurology. https://doi.org/10.1001/jamaneurol.2021.3310
Vancouver
Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, et al. Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial. JAMA neurology. 2021. doi:10.1001/jamaneurol.2021.3310. PMID: 34570177.
BibTeX
@article{vossel2021-34570177,
author = {Vossel, K. and Ranasinghe, K. G. and Beagle, A. J. and La, A. and Ah Pook, K. and Castro, M. and Mizuiri, D. and Honma, S. M. and others},
title = {{Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial}},
journal = {JAMA neurology},
year = {2021},
doi = {10.1001/jamaneurol.2021.3310},
pmid = {34570177},
url = {https://doi.org/10.1001/jamaneurol.2021.3310}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Of 54 adults assessed for eligibility, 11 did not meet study criteria, and 9 declined to participate.
- Overall, treatment with levetiracetam did not change NIH-EXAMINER composite scores (mean difference vs placebo, 0.07 points; 95% CI, -0.18 to 0.32 points; P = .55) or secondary measures.
Why it matters
In this randomized clinical trial, treatment with levetiracetam did not change NIH-EXAMINER composite scores or secondary measures compared with placebo. The study found no significant benefit of levetiracetam on cognition in patients with Alzheimer disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants34
- Effect size61.8%; 38.2%; 82.4%
- Evidence strengthHigh
How this study scored 74/100
Published in a leading specialty journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 34 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 5 / 7 | Cited 275 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 39.3 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 5 / 6 | Cited 24.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 185 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Heidi E. Kirsch: h-index 43 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Los Angeles: institution h-index 1,923 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34570177) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2021.3310
- PubMed: 34570177
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.